-Reuters
FDA Rejects Supernus Pharma’s Minimally Invasive Parkinson’s Therapy
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) received FDA’s complete response letter (CRL) for the SPN-830 marketing application. SPN-830 is an investigational apomorphine infusion…